For example, certain mutations, such as HER2 amplification in breast cancer (25–27) or KRAS mutations in colorectal cancer (28, 29), help classify tumors into distinct subtypes, guiding treatment decisions and predicting prognosis. Here, ERBB2 is linked to breast carcinoma.